Novel 4-azasteroid, dual 5-alpha reductase (type 1 and 2 isozymes) inhibitor with steroid structure (azasteroid). Not an antiandrogen.
Mechanism:
FCE 28260, reversibly inhibit 5 alpha-reductase in competitive mode, resulting in suppression of serum DHT.
Experimental studies on adult male rats, show, that FCE28260 reduced prostatic DHT 24 h after administration by 74% reduction in prostate DHT (compare: Finasteride reduce DHT in this system by 26%).
No studies on the model of human androgenetic alopecia is known. |
|
|
|
